Bevacizumab (Avastin) for Ocular Disorders

Authors

  • Shweta Walia Assistant Professor, Department of Ophthalmology MGMMC & MYH Hospital, Indore, MP, ,
  • P. Varma Dean and CEO MGMMC & MYH Hospital, Indore, MP,

DOI:

https://doi.org/10.7439/ijpr.v3i4.55

Abstract

Abnormal ocular neovascularization is major cause of loss of vision.The newly formed vessels are dysfunctional which can leak fluid, cause hemorrhage, or are associated with fibrous proliferation, resulting in potentially catastrophic loss of vision. Anti VEGF have come as a boon to cure ocular neovascularization. This paper will describe the attempted uses of bevacizumab , humanized monoclonal antibody to VEGF, for various ocular disorders and its efficacy in addition to discussing safety. Comments regarding appropriate use of this treatment are based on our current level of knowledge and large ,randomized control studies are required to expand the use of this wonderful drug.

Downloads

Download data is not yet available.

Author Biography

  • Shweta Walia, Assistant Professor, Department of Ophthalmology MGMMC & MYH Hospital, Indore, MP, ,
    ASSSISTANT PROFESSOR

Downloads

Published

2013-12-30

Issue

Vol. 3 No. 4 (2013): Oct- Dec

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Author must Submit Copyright form  After acceptance of Article

How to Cite

1.
Walia S, Varma P. Bevacizumab (Avastin) for Ocular Disorders. Int J of Pharmc Res [Internet]. 2013 Dec. 30 [cited 2025 Mar. 14];3(4):59-68. Available from: https://ssjournals.co.in/index.php/ijpr/article/view/1239
Crossref
Scopus
Google Scholar
Europe PMC